Lv42
420 积分 2021-08-12 加入
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
1个月前
已完结
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
1个月前
已完结
Systemic Lupus Erythematosus A Review
1个月前
已完结
[Chinese guideline for the diagnosis and treatment of Takayasu's arteritis(2023)]
1个月前
已完结
Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective
2个月前
已完结
The Role of CLDN18.2 in Gastric Cancer Prognosis: A Systematic Review and Meta-Analysis
4个月前
已完结
172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
4个月前
已完结
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
